A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs DCC 2618 (Primary)
- Indications Gastrointestinal stromal tumours; Glioma; Haematological malignancies; Solid tumours; Systemic mastocytosis
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Deciphera Pharmaceuticals
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
- 11 Sep 2017 Updated results from patients with gastrointestinal stromal tumors (GIST) (n = 57) published in a Deciphera Pharmaceuticals media release.
- 31 Aug 2017 According to a Deciphera Pharmaceuticals media release, updated data will be presented at the 2017 European Society for Medical Clinical Oncology Annual Congress (ESMO).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History